Literature DB >> 15802019

pRb-Independent growth arrest and transcriptional regulation of E2F target genes.

Michael T McCabe1, Odinaka J Azih, Mark L Day.   

Abstract

The retinoblastoma tumor suppressor (pRb) has traditionally been studied as a negative regulator of cell cycle progression through its interactions with the E2F family of transcription factors. Utilizing prostate epithelial cell lines established from Rb+/+ and Rb-/- prostate tissues, we previously demonstrated that Rb-/- epithelial cells were not transformed and retained the ability to differentiate in vivo despite the lack of pRb. To further study the effects of pRb loss in an epithelial cell population, we utilized oligonucleotide microarrays to identify any pRb-dependent transcriptional regulation during serum depletion-induced growth arrest. These studies identified 120 unique transcripts regulated by growth arrest in Rb+/+ cells. In these wild-type cells, the majority (80%) of altered transcripts were downregulated, including 40 previously identified E2F target genes. Although the transcriptional repression of E2F target genes is characteristic of pRb pocket protein family activity, further analysis revealed that, compared to Rb+/+ cells, Rb-/- cells exhibited a nearly identical response for all transcripts including those of E2F target genes. These findings demonstrate that pRb is not strictly required for the vast majority of transcriptional alterations associated with growth arrest.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802019      PMCID: PMC1501127          DOI: 10.1593/neo.04394

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  52 in total

1.  E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis.

Authors:  H Müller; A P Bracken; R Vernell; M C Moroni; F Christians; E Grassilli; E Prosperini; E Vigo; J D Oliner; K Helin
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

2.  Transcriptional regulation and function during the human cell cycle.

Authors:  R J Cho; M Huang; M J Campbell; H Dong; L Steinmetz; L Sapinoso; G Hampton; S J Elledge; R W Davis; D J Lockhart
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

3.  Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.

Authors:  J Sage; G J Mulligan; L D Attardi; A Miller; S Chen; B Williams; E Theodorou; T Jacks
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

4.  Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions.

Authors:  J H Dannenberg; A van Rossum; L Schuijff; H te Riele
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

5.  Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis.

Authors:  S Ishida; E Huang; H Zuzan; R Spang; G Leone; M West; J R Nevins
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control.

Authors:  M Classon; S Salama; C Gorka; R Mulloy; P Braun; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 7.  Retinoblastoma protein partners.

Authors:  E J Morris; N J Dyson
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

Review 8.  The retinoblastoma gene: a prototypic and multifunctional tumor suppressor.

Authors:  L Zheng; W H Lee
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

9.  Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis.

Authors:  Amy S Weinmann; Pearlly S Yan; Matthew J Oberley; Tim Hui-Ming Huang; Peggy J Farnham
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

10.  Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth.

Authors:  W R Sellers; B G Novitch; S Miyake; A Heith; G A Otterson; F J Kaye; A B Lassar; W G Kaelin
Journal:  Genes Dev       Date:  1998-01-01       Impact factor: 11.361

View more
  6 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Authors:  Ankur Sharma; Clay E S Comstock; Erik S Knudsen; Khanh H Cao; Janet K Hess-Wilson; Lisa M Morey; Jason Barrera; Karen E Knudsen
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

3.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.

Authors:  Yuen-Li Chung; Helen Troy; Rebecca Kristeleit; Wynne Aherne; L Elizabeth Jackson; Peter Atadja; John R Griffiths; Ian R Judson; Paul Workman; Martin O Leach; Mounia Beloueche-Babari
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

Review 4.  Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.

Authors:  R Adam Smith; Saffet Guleryuz; H Charles Manning
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

5.  High levels of global genome methylation in patients with retinoblastoma.

Authors:  Hülya Yazici; Hui-Chen Wu; Hulya Tigli; Elif Z Yilmaz; Rejin Kebudi; Regina M Santella
Journal:  Oncol Lett       Date:  2020-05-13       Impact factor: 2.967

6.  Retinoblastoma and its binding partner MSI1 control imprinting in Arabidopsis.

Authors:  Pauline E Jullien; Assaf Mosquna; Mathieu Ingouff; Tadashi Sakata; Nir Ohad; Frédéric Berger
Journal:  PLoS Biol       Date:  2008-08-12       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.